ENTITY

IVERIC bio (ISEE US)

4
Analysis
Health CareUnited States
IVERIC bio, Inc. operates as a biopharmaceutical company. The Company develops treatments for patients with orphan inherited retinal diseases with significant unmet medical needs. IVERIC bio serves customers in the United States.
more
bullishAstellas Pharma
02 May 2023 08:35

Astellas Pharma Buys Iveric Bio: Help Offset Upcoming Patent Expiry of XTANDI

Acquisition of Iveric Bio's key drug asset ACP should offer protection against upcoming patent expiry of XTANDI. The whole deal is based on a late...

Share
bullishAstellas Pharma
02 May 2023 01:07

Astellas Pharma (4503 JP): New Acquisition to Add Promising Drug Candidate in New Therapeutic Area

Astellas Pharma is acquiring Iveric Bio for ~$5.9B. Iveric’s lead drug candidate ACP will be a revenue-generating pillar to compensate for the...

Logo
279 Views
Share
bullishIVERIC bio
13 Dec 2016 13:58

Ophthotech: What Is Next?

We listened to the conference call by Ophthotech Corp (OPHT US) management (link). The results of the phase 3 trial were shocking to many investors...

bullishIVERIC bio
06 Dec 2016 14:21

New Long Position: Novel Drug for Wet-AMD, a Common Cause of Blindness, and Upcoming Catalyst.

We opened a new long position today in Ophthotech Corp (OPHT US), an emerging biotechnology company that is developing novel drugs for wet-type...

No more insights
x